The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. AnaptysBio Inc shares valued at $163,192 were sold by Lizzul Paul F. on Jan 08 ’26. At $44.71 per share, Lizzul Paul F. sold 3,650 shares. The insider’s holdings dropped to 42,088 shares worth approximately $2.12 million following the completion of this transaction.
Also, Paul F. Lizzul purchased 3,650 shares, netting a total of over 165,016 in proceeds.
Before that, MULROY DENNIS had sold 2,515 shares from its account. In a trade valued at $112,446, the CHIEF FINANCIAL OFFICER traded AnaptysBio Inc shares for $44.71 each. Upon closing the transaction, the insider’s holdings decreased to 2,515 shares, worth approximately $1.1 million.
Analysts at Barclays started covering the stock with ‘”an Overweight”‘ outlook in a report released in mid October. As of June 04, 2025, H.C. Wainwright has increased its “Neutral” rating to a “Buy” for ANAB. Earlier on February 04, 2025, Wolfe Research initiated its rating. Their recommendation was “an Outperform” for ANAB stock.
Analyzing ANAB Stock Performance
On last trading session, AnaptysBio Inc [NASDAQ: ANAB] rose 4.44% to $50.26. The stock’s lowest price that day was $46.73, but it reached a high of $50.38 in the same session. During the last five days, there has been a surge of approximately 11.17%. Over the course of the year, AnaptysBio Inc shares have jumped approximately 243.78%.
Is AnaptysBio Inc subject to short interest?
Stocks of AnaptysBio Inc saw a sharp steep in short interest on 2025-12-31 dropping by -0.72 million shares to 5.14 million. Data from Yahoo Finance shows that the short interest on 2025-11-28 was 5.86 million shares. A decline of -14.02% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 11.65 of the overall float, the days-to-cover ratio (short ratio) decline to 11.65.
Which companies own the most shares of AnaptysBio Inc (ANAB)?
In terms of AnaptysBio Inc share price expectations, FactSet research, analysts set an average price target of 56 in the next 12 months, up nearly 16.38% from the previous closing price of $48.12. Analysts anticipate AnaptysBio Inc stock to reach 140 by 2026, with the lowest price target being 36. In spite of this, 6 analysts ranked AnaptysBio Inc stock as Buy at the end of 2026. On December 11, 2024, H.C. Wainwright assigned a price target of “a Neutral” to the stock and downgraded coverage with a $19.
